| Haemorrhagic event | ||
|---|---|---|
| UGIH | ICH | |
| Cases (n (%)) | 108 (70.1) | 46 (29.9) |
| Age (years) (mean (range)) | 67.2 (25–104) | 74 (42–100) |
| Women (n (%)) | 34 (31.5) | 18 (39.1) |
| Under acenocumarol therapy (n (%)) | 10 (6.5) | 9 (5.8) |
| Under DOAC therapy (n (%)) | 4 (2.6) | 3 (1.9) |
| Apixaban | 1 | 2 |
| Dabigatran | 1 | 0 |
| Edoxaban | 2 | 0 |
| Rivaroxaban | 0 | 1 |
| Incorrect DOAC posology | 1 | 0 |
| Appropriate indication | 4 | 3 |
| NSAID | 0 | 0 |
| GC | 0 | 0 |
| SSRI | 1 | 0 |
| PAA | 1 | 1 |
| Total risk drugs | 2 | 1 |
| Gastric lesions | 4 | 0 |
| Liver disease | 0 | 0 |
| Coagulopathy | 0 | 0 |
| Hypertension | 4 | 3 |
| Total risk comorbidities | 8 | 3 |